Fairtree Asset Management Pty Ltd Acquires Shares of 1,976 United Therapeutics Corporation $UTHR

Fairtree Asset Management Pty Ltd bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, HoldingsChannel reports. The firm bought 1,976 shares of the biotechnology company’s stock, valued at approximately $1,071,000.

Other hedge funds also recently made changes to their positions in the company. Leuthold Group LLC lifted its position in shares of United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after buying an additional 3,126 shares during the last quarter. UBS Group AG grew its position in shares of United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after buying an additional 70,445 shares during the last quarter. Nicholas Investment Partners LP grew its position in shares of United Therapeutics by 478.5% during the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after buying an additional 3,766 shares during the last quarter. M&T Bank Corp raised its stake in United Therapeutics by 171.6% during the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock worth $1,531,000 after acquiring an additional 1,985 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new stake in United Therapeutics during the fourth quarter worth about $633,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research reports. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Royal Bank Of Canada dropped their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Bank of America cut their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Finally, JPMorgan Chase & Co. boosted their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Stock Down 1.5%

Shares of NASDAQ:UTHR opened at $521.00 on Friday. The company has a market cap of $22.35 billion, a PE ratio of 18.64, a P/E/G ratio of 1.79 and a beta of 0.59. The company’s 50-day moving average price is $533.74 and its 200 day moving average price is $537.53. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period in the previous year, the business posted $6.41 EPS. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. As a group, equities analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current year.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,356,182.60. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $170,968,483.28. This trade represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 434,275 shares of company stock worth $234,984,268. Corporate insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.